Literature DB >> 27198772

Efficacy and productive performance of moxidectin in feedlot calves infected with nematodes resistant to ivermectin.

L E Fazzio1, N Streitenberger2, W R Galvan2, R O Sánchez3, E J Gimeno4, R E F Sanabria4.   

Abstract

Anthelmintic resistance (AR) of gastrointestinal nematodes to macrocyclic lactones is an increasingly common worldwide phenomenon limiting cattle production. This has motivated the search for alternatives, such as new active compounds, added drug synergisms, different doses, and alternate administration routes. The aim of this study was the assessment of moxidectin (MXD) performance in feedlot calves with a history of AR to ivermectin (IVM). Crossbred female calves aged 6-7 months and weighing 163kg (SD=34kg) were divided into 3 groups of 35 animals each. They were assigned to the following antiparasitic treatment groups: IVM group (0.2mg/kg IVM); MXD group (0.2mg/kg MXD), and ricobendazole+levamisole (RBZ+LEV) group (7.5mg/kg RBZ+8mg/kg LEV). On days 0, 26, and 47, fecal samples were taken and the weight of each animal was registered. Anthelmintic efficacy (by fecal egg count reduction), total weight gain (TWG) and average daily weight gain (AWG) were compared between the groups. A mixed SAS procedure was used for statistical analysis. Fecal egg count reduction 26 days post-treatment (PT) was calculated at 28% for the IVM group, 85% for the MXD group, and 99% for the RBZ+LEV group. AWGs (Standard Error) of 1.095g (56), 1.264g (49), and 1.340g (52) were registered for the IVM, MXD, and RBZ+LEV groups, respectively (p<0.05). Coprocultures revealed that MXD more effectively reduced Haemonchus spp. and Cooperia spp. egg counts than IVM. This resulted in higher AWGs and TWGs for this group; similar results were seen for the RBZ+LEV group as well. In this study, animals treated with MXD gained about 160 more g/day than animals treated with IVM. This represents a gain of 16 USD per animal over the 47 day trial.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Average weight gain; Cattle; Cooperia; Haemonchus; Macrocyclic lactones

Mesh:

Substances:

Year:  2016        PMID: 27198772     DOI: 10.1016/j.vetpar.2016.04.003

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  5 in total

1.  Impacts of a post-transport/pre-processing rest period on the growth performance, anthelmintic efficacy, and serum metabolite changes in cattle entering a feed yard.

Authors:  Payton L Dahmer; Charles A Zumbaugh; Macie E Reeb; Nicole B Stafford; Zachary T Buessing; Kenneth G Odde; James S Drouillard; A J Tarpoff; Cassandra K Jones
Journal:  Transl Anim Sci       Date:  2022-06-21

2.  Poloxamer 407/188 Binary Thermosensitive Gel as a Moxidectin Delivery System: In Vitro Release and In Vivo Evaluation.

Authors:  Xiangchun Ruan; Jidong Hu; Lianshou Lu; Youwei Wang; Chunlian Tang; Faquan Liu; Xiuge Gao; Li Zhang; Hao Wu; Xianhui Huang; Qing Wei
Journal:  Molecules       Date:  2022-05-10       Impact factor: 4.927

3.  Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model.

Authors:  Charlotte Bernigaud; Fang Fang; Katja Fischer; Anne Lespine; Ludwig Serge Aho; Dominique Dreau; Andrew Kelly; Jean-François Sutra; Francis Moreau; Thomas Lilin; Françoise Botterel; Jacques Guillot; Olivier Chosidow
Journal:  PLoS Negl Trop Dis       Date:  2016-10-12

Review 4.  Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance.

Authors:  Roger K Prichard; Timothy G Geary
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-06-15       Impact factor: 4.077

5.  Moxidectin inhibits glioma cell viability by inducing G0/G1 cell cycle arrest and apoptosis.

Authors:  Dandan Song; Hongsheng Liang; Bo Qu; Yijing Li; Jingjing Liu; Chen Chen; Daming Zhang; Xiangtong Zhang; Aili Gao
Journal:  Oncol Rep       Date:  2018-07-12       Impact factor: 3.906

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.